Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 7/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6029063 | 0.93 | PPARD (0.47) | PPARDMCL1PPARAGRIN2BPPARG | |
| SCHEMBL6029767 | 0.89 | PPARD (0.49) | TRPV1PPARDMCL1PPARAPPARG | |
| SCHEMBL6017577 | 0.88 | ALDH1A1 (0.43) | TRPV1PPARDMCL1PPARAALDH1A1 | |
| SCHEMBL6030670 | 0.87 | PPARD (0.40) | TRPV1PPARDMCL1PPARAGRIN2B | |
| SCHEMBL6028662 | 0.84 | PPARD (0.39) | TRPV1PPARDMCL1PPARAALDH1A1 | |
| SCHEMBL5027024 | 0.83 | TRPV1 (0.43) | TRPV1PPARDMCL1PPARAGRIN2B | |
| SCHEMBL6017238 | 0.83 | PPARD (0.37) | TRPV1PPARDMCL1PPARAALDH1A1 | |
| SCHEMBL5617221 | 0.81 | PPARD (0.59) | PPARDMCL1PPARAGRIN2BPPARG | |
| SCHEMBL5016803 | 0.81 | PPARD (0.40) | TRPV1PPARDMCL1PPARAALDH1A1 | |
| SCHEMBL5022631 | 0.81 | TRPV1 (0.39) | TRPV1PPARDMCL1PPARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995263-B2 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050096353-A1 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096353-A1 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | TRPV1 651/4885PPARD 1/4885MCL1 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.